Our Drug Discovery series continues with our 3rd Annual Drug Discovery: Easing The Bottleneck conference.
The production of new drugs has always been paramount for pharmaceutical manufacturers, but with key patents now expiring, cost effective drug discovery is more important than ever. This event will bring together the foremost experts on compound management, gene expression, and other pertinent areas to the drug discovery process. Through targeted panel discussion our delegates will learn how to improve speed to market, increase profit margins, and most importantly: develop new, effective drugs and biotechnology.
This event will be co-located with our 3rd Annual Drug Discovery Partnerships: Filling the Pipeline 2011.
Conference Registration Prices:
Pharmaceutical Companies- First 100 Free! Pharmaceutical Companies Standard Price - $495
Service Provider Reduced Registration until September 16, 2011- ($795 USD) SAVE $200! Service Provider Standard Registration - ($995 USD)
Opal Events' 3rd AnnualDrug Discovery: Easing the Bottleneck 2011 conference has been researched and developed specifically for; Pharmaceuticals, Biotech, Academia, Foundation, Technology Companies, and CROs' VP/ Director/ Manager/ Faculty Advisor of:
• External Research Collaboration • Scientific Affairs • Business Development • Partnership/ Alliance Management • Office of Technology Transfer • Academic Screening Facilities • School of Medicine/ Life Sciences/ Pharmacy • Grants Manager • Program Office
• Research & Development • Analytical/ Medicinal Chemistry • Sample/ Compound Management • Assay Development • Lead Discovery/ Optimization • High Throughput Screening (HTS) • Automation • ADMET
Government officials, compliance officers, individuals from university and research institutes will also find much to benefit from in attending this comprehensive event.
Join us for :
15+ panels, discussions and presentations of the most relevant, pertinent information to the drug discovery process
Stimulating discussions on the roles and responsibilities in drug discovery management, as well as new and innovative technologies and strategies
